Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention

被引:30
|
作者
Bonnington, Oliver [1 ]
Harris, Magdalena [1 ]
机构
[1] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England
关键词
Peer support; Hepatitis C virus; PWID; Qualitative methods; Injection drug use; Treatment; VIRUS-INFECTION; DRUG-USERS; INJECT DRUGS; PEOPLE; EDUCATION; SERVICES; BARRIERS;
D O I
10.1016/j.drugpo.2017.05.031
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Peer support and involvement is recognised as a vital component of hepatitis C (HCV) treatment provision for marginalised populations, such as people who inject drugs (PWID). Developments in HCV treatments enable increased provision in community settings - expanding the possibilities for meaningful peer involvement in HCV treatment plans. To date, HCV peer support has generally been viewed as a positive intervention, with little critical reflection on the ways social structures, policies, health and drug services and social identity impact on how peer support is experienced and received. Methods: We report on the qualitative component of a UK-based intervention designed to increase HCV diagnosis and treatment in primary care and drug treatment settings. Data were collected between 2014 and 2016. Pre-intervention, a total of 35 PWID clients took part in nine in-depth interviews and four focus groups. In addition, 22 drug services and intervention providers took part in two focus groups and nine interviews. Post-intervention, one focus group and eight interviews were conducted with 13 PWID clients, and four focus groups and ten interviews were conducted with 26 drug services and intervention providers. Our data generation and thematic analysis focused on the peer education and buddy support component of the intervention. Results: Participants had common expectations of the peer role (to 'just be there') and its occupants' attributes (empathy, trustworthy, etc.). However, in practice, peers faced constraints on realising these expectations. A 'recovery' dominated drug treatment ethos in the UK appeared to influence the selection of 'recovery champions' as peers for the intervention. This created tensions in relations with clients, particularly when rislc-adverse discourses were internalised by the peers. Peers were poorly integrated and supported within the service, affecting opportunities to relate and build trust with clients. Thus, the scope for peer support to impact on the nature and extent of clients' testing and treatment for HCV was limited. Conclusion: The efficacy of peer involvement can be constrained by organisational structures and boundaries - especially regarding who is deemed to be 'a peer'. Peer programmes take time and care to implement and weave into wider recovery and harm reduction frameworks. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:221 / 229
页数:9
相关论文
共 50 条
  • [31] The Egyptian hepatitis C programme: A model of HCV treatment intervention?
    Lemoine, M.
    Cooke, G. S.
    JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 638 - 639
  • [32] RAPID HEPATITIS C TEST AND TREAT WITH PEER SUPPORT AT OPIOID TREATMENT PROGRAMS (RAPID HCV): A MULTICENTER RANDOMIZED CONTROL TRIAL
    Falade-Nwulia, Oluwaseun
    Price, Jennifer
    Feld, Jordan
    Eaton, Ellen
    Ricardo, Franco
    Barnaba, Brittany
    Brown, Diane
    Hussain, Sarah
    Wren, Catherine
    Sari, Hamidreza Karimi
    Hirose, Kyoko
    Cavacuiti, Chris
    O'rear, Stephen
    Capraru, Camelia
    Tobin, Karin
    Schwartz, Sheree
    Sulkowski, Mark
    HEPATOLOGY, 2024, 80 : S521 - S522
  • [33] Frequency of Depression in patients of Chronic Hepatitis C who had not yet received treatment
    Adam, Abdullahi
    Chachar, Aijaz Zeeshan Khan
    Haider, Miqdad
    Yaqoob, Nazish
    Asif, Mohsin
    Ali, Mubbashir
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (06): : 1407 - 1410
  • [34] Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferon
    Genryu Hirano
    Atsushi Fukunaga
    Tetsuro Sohda
    Hideo Kunimoto
    Kaoru Yotsumoto
    Kunitoshi Sakurai
    Hideyuki Iwashita
    Shuichi Ueda
    Keiji Yokoyama
    Daisuke Morihara
    Yoshitaka Tomioka
    Akira Anan
    Masashi Yamaguchi
    Yasuaki Takeyama
    Kouichi Eguchi
    Masaharu Sakamoto
    Makoto Irie
    Kaoru Iwata
    Satoshi Shakado
    Kunihiko Aoyagi
    Shotaro Sakisaka
    Clinical Journal of Gastroenterology, 2012, 5 (2) : 127 - 130
  • [35] Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferon
    Hirano, Genryu
    Fukunaga, Atsushi
    Sohda, Tetsuro
    Kunimoto, Hideo
    Yotsumoto, Kaoru
    Sakurai, Kunitoshi
    Iwashita, Hideyuki
    Ueda, Shuichi
    Yokoyama, Keiji
    Morihara, Daisuke
    Tomioka, Yoshitaka
    Anan, Akira
    Yamaguchi, Masashi
    Takeyama, Yasuaki
    Eguchi, Kouichi
    Sakamoto, Masaharu
    Irie, Makoto
    Iwata, Kaoru
    Shakado, Satoshi
    Aoyagi, Kunihiko
    Sakisaka, Shotaro
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2012, 5 (02) : 127 - 130
  • [36] Approach to the Treatment-Experienced Patient with Hepatitis C Virus Genotype 1 Infection
    Flemming, Jennifer A.
    Terrault, Norah A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2012, 26 (04) : 903 - +
  • [37] Practising critical resilience as an advanced peer support worker in London: A qualitative evaluation of a peer-led hepatitis C intervention amongst people experiencing homelessness who inject drugs
    Surey, Julian
    Francis, Marie
    Gibbons, John
    Leonard, Mark
    Abubakar, Ibrahim
    Story, Alistair
    MacLellan, Jennifer
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 91
  • [38] Prioritizing Treatment Experienced Patients with Hepatitis C Infection for Treatment with Telaprevir: a Number Needed to Treat Approach
    Rowe, Ian A.
    Armstrong, Matthew J.
    Houlihan, Diarmaid D.
    HEPATOLOGY, 2012, 55 (05) : 1644 - 1645
  • [39] Lower SVR Rates in Treatment Experienced Cirrhotic Veterans for Hepatitis C Genotype 1
    Negusse, Deborah
    Imbertson, Erick
    Peplinski, Brandon
    Florian, Rosemarie
    Strong, Richard
    Chao, Daniel
    Jackson, Christian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S361 - S361
  • [40] HEPATITIS Treatment of chronic hepatitis C-how much interferon is enough?
    Ferenci, Peter
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (04) : 191 - 193